Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...

A day of celebration that Forestville Elementary School has fostered for more than four decades was held last month. The ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with ...

Figure 2: Classification of the poly-ADP-ribose-polymerase (PARP) family according to the structural model proposed by Kleine et al.7. To identify the PARP10 residues that are post-translationally ...

Eisbach Bio plans to use a $4.75m grant to advance EIS-12656, a small molecule ALC1 inhibitor to disrupt the genome structure in hard-to-treat cancer cells, says CEO Dr. Adrian Schomburg.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Therapeutics announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating ...

Her team recently developed a small nanocarrier that actively delivers a poly (ADP-ribose) polymerase (PARP) inhibitor and a demethyltransferase 1 (DNMT1) inhibitor to tumors in mouse cancer models. 1 ...

PARP kicked off on Feb. 6 with an evening event organized by library media specialist Tara Gonzalez. More than 150 students visited the reading stations led by teachers and parent volunteers.